Table 3

Safety outcomes according to eGFR category in patients treated with tenecteplase

	eGFR (mL/min/1.73 m²)	Event rate (%)	Crude OR (95% CI)	P value	Adjusted OR (5% CI)*	P value
Symptomatic intracranial haemorrhage within 36 hours	≥90	7 (1.5)	1		1
	60–89	7 (3.6)	2.44 (0.84 to 7.04)	0.10	2.01 (0.59 to 6.85)	0.27
	<60	1 (2.2)	1.49 (0.18 to 12.36)	0.71	0.92 (0.09 to 9.47)	0.95
Symptomatic intracranial haemorrhage within 90 days	≥90	8 (1.7)	1		1
	60–89	7 (3.6)	2.13 (0.76 to 5.95)	0.15	1.77 (0.55 to 5.66)	0.34
	<60	2 (4.4)	2.66 (0.55 to 12.91)	0.23	1.86 (0.31 to 11.16)	0.50
Parenchymal haematoma 2 intracranial haemorrhage within 90 days	≥90	6 (1.3)	1		1
	60–89	2 (1.0)	0.79 (0.16 to 3.96)	0.78	0.92 (0.16 to 5.40)	0.92
	<60	2 (4.4)	3.56 (0.70 to 18.17)	0.13	4.68 (0.63 to 34.88)	0.13
Any intracranial haemorrhage within 90 days	≥90	23 (4.9)	1		1
	60–89	15 (7.7)	1.6 (0.82,3 to 14)	0.17	1.40 (0.65 to 3.01)	0.39
	<60	6 (13.3)	2.96 (1.14 to 7.69)	0.03	2.13 (0.7 to 6.50)	0.18
Death within 90 days	≥90	16 (3.4)	1		1
	60–89	19 (9.8)	3.21 (1.62 to 6.33)	0.008	3.39 (1.53 to 7.53)	0.003
	<60	10 (22.2)	8.02 (3.39 to 18.98)	<0.001	8.95 (3.07 to 26.13)	<0.001
Adverse events within 90 days	≥90	384 (82.2)	1		1
	60–89	177 (91.2)	2.28 (1.31 to 3.95)	0.004	2.00 (1.11 to 3.59)	0.02
	<60	44 (97.8)	9.55 (1.30 to 70.21)	0.027	7.73 (1.03 to 58.21)	0.047
Serious adverse events within 90 days	≥90	62 (13.3)	1		1
	60–89	36 (18.6)	1.52 (0.97 to 2.38)	0.07	1.36 (0.82 to 2.23)	0.23
	<60	17 (37.8)	3.95 (2.04 to 7.63)	<0.001	3.35 (1.62 to 6.95)	0.001

Data are expressed as n/N (%), effect size (95% CI) or p value.
ORs of the safety outcomes were calculated with their 95% CIs using binary logistic regression.
*The models were adjusted for age, sex, baseline National Institutes of Health Stroke Scale, history of hypertension, history of antiplatelet and anticoagulant drug use, onset-to-needle time and bridging thrombectomy.
eGFR, estimated glomerular filtration rate.